Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-25-013824
Filing Date
2025-04-30
Accepted
2025-04-30 15:34:55
Documents
17
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A mnpr20250418_def14a.htm   iXBRL DEF 14A 517847
6 monologo.jpg GRAPHIC 10014
7 monosig.jpg GRAPHIC 3062
  Complete submission text file 0001437749-25-013824.txt   866237

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mnpr-20241231.xsd EX-101.SCH 4575
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mnpr-20241231_def.xml EX-101.DEF 1590
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnpr-20241231_lab.xml EX-101.LAB 1775
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnpr-20241231_pre.xml EX-101.PRE 741
20 EXTRACTED XBRL INSTANCE DOCUMENT mnpr20250418_def14a_htm.xml XML 10453
Mailing Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091
Business Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 8473880349
Monopar Therapeutics (Filer) CIK: 0001645469 (see all company filings)

EIN.: 320463781 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39070 | Film No.: 25894518
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)